Page 65 - Read Online

Lee. Vessel Plus 2022;6:7 https://dx.doi.org/10.20517/2574-1209.2021.31 Page 5 of 5

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Gault J, Sain S, Hu LJ, Awad IA. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery
2006;59:1278-84; discussion 1284-5. DOI PubMed
2. Shenkar R, Shi C, Rebeiz T, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10
mutations. Genet Med 2015;17:188-96. DOI PubMed PMC
3. Tang AT, Sullivan KR, Hong CC, et al. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.
Sci Transl Med 2019;11:eaaw3521. DOI PubMed PMC
4. Gunel M, Awad IA, Finberg K, et al. A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl
J Med 1996;334:946-51. DOI PubMed
5. Liquori CL, Berg MJ, Squitieri F, et al. Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am J Hum Genet
2007;80:69-75. DOI PubMed PMC
6. U.S. Food & Drug Administration. Enhancing the diversity of clinical trial populations - eligibility criteria, enrollment practices, and
trial designs guidance for industry, November 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-
documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial [Last accessed on 2 Nov
2021].